2015至2017年骨转移放疗趋势:复杂放疗时代的明智选择
该研究基于覆盖84%受益人的Medicare索赔数据,分析2015至2017年骨转移放疗的使用趋势与支出。在40,993次骨转移放疗中,63%为短程EBRT,24%为长程EBRT,7%为SBRT,6%为IMRT;长程EBRT绝对减少8%,短程EBRT、SBRT和IMRT分别增加4%、2.5%和1%。约1/4患者接受长程EBRT,其减少部分被复杂治疗模式替代,但复杂模式支出随时间下降。
要点
- 骨转移放疗中63%为短程EBRT,24%为长程EBRT,7%为SBRT,6%为IMRT。
- 2015至2017年长程EBRT绝对减少8%,短程EBRT、SBRT和IMRT分别增加4%、2.5%和1%。
- SBRT与短程EBRT的支出差异在专业费用上相对缩小8%,在技术费用上缩小12%。
核心结论
- 约1/4患者接受长程EBRT,其使用小幅减少但大部分被复杂治疗模式替代。
- 复杂模式的支出随时间下降。
- 随着替代支付模式生效,需要质量指标确保复杂技术的适当、有效和安全实施。
研究设计与样本
- 基于覆盖84%受益人的Medicare索赔数据集,分析2015至2017年骨转移放疗趋势。
- 在467,781次放疗 episodes 中识别出40,993次骨转移放疗。
- 比较医院附属门诊与独立中心在短程EBRT、长程EBRT、IMRT和SBRT的使用差异。
- 使用卡方检验或Wilcoxon秩和检验比较分类和连续变量,采用多变量逻辑/线性回归识别与模式、分割和支出的关联。
主要发现
- 骨转移放疗 episodes 占所有放疗的9.4%,2015至2017年总体比例稳定,但医院附属门诊设置的治疗增加(P < .005)。
- 医院附属门诊短程EBRT占69%、SBRT占9%,独立中心分别为56%和5%。
- 独立中心长程EBRT占31%、IMRT占9%,医院附属门诊分别为19%和4%。
- SBRT/IMRT的使用率在不同设置间无差异(P = .4)。
- SBRT与短程EBRT的支出差异在专业费用上相对缩小8%,技术费用上缩小12%。
关键数值与推荐
- 指南推荐骨转移采用短程(≤10次)外照射放疗(EBRT)。
- SBRT可能改善结局,但不推荐在临床试验外常规使用。
临床怎么用
- 骨转移放疗应优先考虑短程EBRT以符合指南推荐。
- SBRT和IMRT的使用需在临床试验框架内或基于质量指标审慎评估。
- 在替代支付模式下,应关注复杂技术的适当性和成本效益。
局限性
- 研究基于Medicare索赔数据,可能受编码准确性影响。
- 仅覆盖2015至2017年,趋势可能随时间变化。
- 未报告患者个体临床特征和结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Guidelines recommend short-course (≤10 fractions) external-beam radiation therapy (EBRT) for bone metastases. Stereotactic body radiation therapy (SBRT) may also improve outcomes; however, routine use is not recommended outside clinical trials. We assessed national radiation therapy trends in complex techniques for bone metastases and associated expenditures. METHODS AND MATERIALS: Using a claims-based Medicare data set covering 84% of beneficiaries, we assessed the relative proportion of all radiation episodes represented by bone metastases. We then evaluated use of short-course and long-course (>10 fractions) EBRT, intensity modulated radiation therapy (IMRT), and SBRT for bone metastases in hospital-affiliated outpatient (OPD) or freestanding (FREE) facilities. We assessed differences using χ2d or Wilcoxon rank sum tests for categorical and continuous variables, respectively. We identified associations with modality, fractionation, and expenditures using multivariable logistic/linear regression. RESULTS: Among 467,781 radiation episodes for 17 cancer diagnoses, the overall proportion of episodes dedicated to bone metastases (9.4%) was stable from 2015 to 2017, although treatments were increasing in the hospital-affiliated outpatient setting (P < .005). We identified 40,993 episodes for bone metastases, of which 63% were short-course EBRT, 24% were long-course EBRT, 7% were SBRT, and 6% were IMRT. Techniques more common in the hospital-affiliated outpatient setting included short-course EBRT (OPD, 69%, vs FREE, 56%) and SBRT (OPD, 9%, vs FREE, 5%). Techniques more common among free-standing centers included long-course EBRT (OPD, 19%, vs FREE, 31%) and IMRT (OPD, 4%, vs FREE, 9%). From 2015 to 2017, long-course EBRT decreased by an absolute 8%; short-course EBRT, SBRT, and IMRT increased by 4%, 2.5%, and 1%, respectively. The SBRT/IMRT uptake did not differ by setting (P = .4). Differences in expenditures between SBRT and short-course EBRT decreased by a relative 8% in professional and 12% in technical fees. CONCLUSIONS: Approximately 1 in 4 patients received long-course EBRT, with small reductions in use largely replaced by complex treatment modalities. However, expenditures for complex modalities also decreased over time. As alternative payment models take effect, quality metrics are needed to ensure appropriate, effective, and safe delivery of complex technologies.
引用
- Santos PMG, Lapen K, Zhang Z, et al. Trends in Radiation Therapy for Bone Metastases, 2015 to 2017: Choosing Wisely in the Era of Complex Radiation. Int J Radiat Oncol Biol Phys. 2020. PMID: 33188862. doi:10.1016/j.ijrobp.2020.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。